Magnetic resonance spectroscopy and metabolic imaging in white matter diseases and pediatric disorders

Topics in Magnetic Resonance Imaging

Volumn 17, Issue 4, 2006, Pages 275-293

  Cecil, Kim M ^a,c   Kos, Radmila Savcic ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Brain; Magnetic resonance spectroscopy; N acetylaspartate; Pediatric; White matter

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID; ALANINE; ASPARTIC ACID; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; INOSITOL; LACTIC ACID; LIPID; MANNITOL; N ACETYLASPARTIC ACID; PROPYLENE GLYCOL; PYRUVIC ACID; SUCCINIC ACID;

ADRENOLEUKODYSTROPHY; ALEXANDER DISEASE; BONE MARROW TRANSPLANTATION; BRAIN DISEASE; CANAVAN DISEASE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; ENCEPHALOMYELITIS; GLOBOID CELL LEUKODYSTROPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFORMATION PROCESSING; LEUKODYSTROPHY; LEUKOENCEPHALOPATHY; METABOLIC DISORDER; METACHROMATIC LEUKODYSTROPHY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; STEM CELL TRANSPLANTATION; WHITE MATTER;

BRAIN DISEASES; CHILD; DEMYELINATING DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; METABOLIC DISEASES;

EID: 34247159464     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e318033787e     Document Type: Review

References (102)

1. Drost DJ, Riddle WR, Clarke GD. Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med Phys. 2002;29:2177-2197.
2. Keevil SF. Spatial localization in nuclear magnetic resonance spectroscopy. Phys Med Biol. 2006;51:R579-R636.
3. Pelletier D, Nelson SJ, Grenier D, et al. 3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain. Magn Reson Imaging. 2002;20:599-606.
4. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med. 2001;46:228-239.
5. Tran TK, Vigneron DB, Sailasuta N, et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med. 2000;43:23-33.
6. Star-Lack J, Vigneron DB, Pauly J, et al. Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses. J Magn Reson Imaging. 1997;7:745-757.
7. Adalsteinsson E, Langer-Gould A, Homer RJ, et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2003;24:1941-1945.
8. Maudsley AA, Darkazanli A, Alger JR, et al. Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. NMR Biomed. 2006;19:492-503.
9. Xu D, Chen AP, Cunningham C, et al. Spectroscopic imaging of the brain with phased-array coils at 3.0 T. Magn Reson Imaging. 2006;24:69-74.
10. Cunningham CH, Vigneron DB, Chen AP, et al. Design of flyback echo-planar readout gradients for magnetic resonance spectroscopic imaging. Magn Reson Med. 2005;54:1286-1289.
11. Mayer D, Kim DH, Adalsteinsson E, et al. Fast CT-PRESS-based spiral chemical shift imaging at 3 Tesla. Magn Reson Med. 2006;55:974-978.
12. Jansen JF, Backes WH, Nicolay K, et al. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology. 2006;240:318-332.
13. van der Voorn JP, Pouwels PJ, Hart AA, et al. Childhood white matter disorders: quantitative MR imaging and spectroscopy. Radiology. 2006;241:510-517.
14. Tallan HH, Moore S, Stein WH. N-Acetyl-L-aspartic acid in brain. J Biol Chem. 1956;219:257-264.
15. Moffett JR, Tieman SB, Weinberger DR, et al. N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System. Bethesda, MD: Springer; 2006, 2004.
16. Clark JF, Doepke A, Filosa JA, et al. N-acetylaspartate as a reservoir for glutamate. Med Hypotheses. 2006;67:506-512.
17. De Stefano N, Bartolozzi ML, Guidi L, et al. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci. 2005;233:203-208.
18. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80:1107-1213.
19. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10:900-919.
20. Barkovich AJ. Pediatric Neuroimaging. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
21. Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005.
22. Kruse B, Hanefeld F, Christen HJ, et al. Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol. 1993;241:68-74.
23. Brockmann K, Dechent P, Wilken B, et al. Proton MRS profile of cerebral metabolic abnormalities in Krabbe disease. Neurology. 2003;60:819-825.
24. Bruhn H, Kruse B, Korenke GC, et al. Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders. J Comput Assist Tomogr. 1992;16:335-344.
25. Tzika AA, Ball WS Jr, Vigneron DB, et al. Clinical proton MR spectroscopy of neurodegenerative disease in childhood. AJNR Am J Neuroradiol. 1993;14:1267-1281. discussion 1282-1264.
26. Tzika AA, Ball WS Jr, Vigneron DB, et al. Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy. Radiology. 1993;189:467-480.
27. Kruse B, Barker PB, van Zijl PC, et al. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol. 1994;36:595-608.
28. Confort-Gouny S, Vion-Dury J, Chabrol B, et al. Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy. Neuroradiology. 1995;37:568-575.
29. Korenke GC, Pouwels PJ, Frahm J, et al. Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients. Pediatr Neurol. 1996;15:103-107.
30. Rajanayagam V, Grad J, Krivit W, et al. Proton MR spectroscopy of childhood adrenoleukodystrophy. AJNR Am J Neuroradiol. 1996;17:1013-1024.
31. Rajanayagam V, Balthazor M, Shapiro EG, et al. Proton MR spectroscopy and neuropsychological testing in adrenoleukodystrophy. AJNR Am J Neuroradiol. 1997;18:1909-1914.
32. Tourbah A, Stievenart JL, Iba-Zizen MT, et al. Localized proton magnetic resonance spectroscopy in patients with adult adrenoleukodystrophy. Increase of choline compounds in normal appearing white matter. Arch Neurol. 1997;54:586-592.
33. Pouwels PJ, Kruse B, Korenke GC, et al. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics. 1998;29:254-264.
34. Salvan AM, Confort-Gouny S, Chabrol B, et al. Brain metabolic impairment in non-cerebral and cerebral forms of X-linked adrenoleukodystrophy by proton MRS: identification of metabolic patterns by discriminant analysis. Magn Reson Med. 1999;41:1119-1126.
35. Izquierdo M, Adamsbaum C, Benosman A, et al. MR spectroscopic imaging of normal-appearing white matter in adrenoleukodystrophy. Pediatr Radiol. 2000;30:621-629.
36. Eichler FS, Barker PB, Cox C, et al. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology. 2002;58:901-907.
37. Eichler FS, Itoh R, Barker PB, et al. Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience. Radiology. 2002;225:245-252.
38. Wilken B, Dechent P, Brockmann K, et al. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. Neuropediatrics. 2003;34:237-246.
39. Liang JS, Lee WT, Hwu WL, et al. Adrenoleukodystrophy: clinical analysis of 9 Taiwanese children. Acta Paediatr Taiwan. 2004;45:272-277.
40. Moser HW, Barker PB. Magnetic resonance spectroscopy: a new guide for the therapy of adrenoleukodystrophy. Neurology. 2005;64:406-407.
41. Oz G, Tkac I, Charnas LR, et al. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology. 2005;64:434-441.
42. Leegwater PA, Vermeulen G, Konst AA, et al. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet. 2001;29:383-388.
43. van der Knaap MS, Leegwater PA, Konst AA, et al. Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. Ann Neurol. 2002;51:264-270.
44. van der Knaap MS, Breiter SN, Naidu S, et al. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology. 1999;213:121-133.
45. van der Knaap MS, Pronk JC, Scheper GC. Vanishing white matter disease. Lancet Neurol. 2006;5:413-423.
46. Pronk JC, van Kollenburg B, Scheper GC, et al. Vanishing white matter disease: a review with focus on its genetics. Ment Retard Dev Disabil Res Rev. 2006;12:123-128.
47. Van Haren K, van der Voorn JP, Peterson DR, et al. The life and death of oligodendrocytes in vanishing white matter disease. J Neuropathol Exp Neurol. 2004;63:618-630.
48. van der Knaap MS, Barth PG, Gabreels FJ, et al. A new leukoencephalopathy with vanishing white matter. Neurology. 1997;48:845-855.
49. Hanefeld F, Holzbach U, Kruse B, et al. Diffuse white matter disease in three children: an encephalopathy with unique features on magnetic resonance imaging and proton magnetic resonance spectroscopy. Neuropediatrics. 1993;24:244-248.
50. van der Knaap MS, van der Voorn P, Barkhof F, et al. A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol. 2003;53:252-258.
51. Linnankivi T, Lundbom N, Autti T, et al. Five new cases of a recently described leukoencephalopathy with high brain lactate. Neurology. 2004;63:688-692.
52. Serkov SV, Pronin IN, Bykova OV, et al. Five patients with a recently described novel leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate. Neuropediatrics. 2004;35:1-5.
53. Hanefeld FA, Brockmann K, Pouwels PJ, et al. Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination. Neurology. 2005;65:701-706.
54. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14:260-264.
55. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-679.
56. Boor PK, de Groot K, Waisfisz Q, et al. MLC1: a novel protein in distal astroglial processes. J Neuropathol Exp Neurol. 2005;64:412-419.
57. Leegwater PA, Boor PK, Yuan BQ, et al. Identification of novel mutations in MLC1 responsible for megalencephalic leukoencephalopathy with subcortical cysts. Hum Genet. 2002;110:279-283.
58. Brockmann K, Finsterbusch J, Terwey B, et al. Megalencephalic leukoencephalopathy with subcortical cysts in an adult: quantitative proton MR spectroscopy and diffusion tensor MRI. Neuroradiology. 2003;45:137-142.
59. van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol. 2001;22:541-552.
60. van der Knaap MS, Ramesh V, Schiffmann R, et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology. 2006;66:494-498.
61. van der Knaap MS, Salomons GS, Li R, et al. Unusual variants of Alexander's disease. Ann Neurol. 2005;57:327-338.
62. Dinopoulos A, Gorospe JR, Egelhoff JC, et al. Discrepancy between neuroimaging findings and clinical phenotype in Alexander disease. AJNR Am J Neuroradiol. 2006;27:2088-2092.
63. Brockmann K, Dechent P, Meins M, et al. Cerebral proton magnetic resonance spectroscopy in infantile Alexander disease. J Neurol. 2003;250:300-306.
64. Madhavarao CN, Moffett JR, Moore RA, et al. Immunohistochemical localization of aspartoacylase in the rat central nervous system. J Comp Neurol. 2004;472:318-329.
65. Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000;123(Pt 12):2407-2422.
66. Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56:1313-1318.
67. Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J. 2004;23:756-764.
68. Wingerchuk DM. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues. Adv Neurol. 2006;98:303-318.
69. Wingerchuk DM. The clinical course of acute disseminated encephalomyelitis. Neurol Res. 2006;28:341-347.
70. Jorens PG, VanderBorght A, Ceulemans B, et al. Encephalomyelitis- associated antimyelin autoreactivity induced by streptococcal exotoxins. Neurology. 2000;54:1433-1441.
71. Becher B, Bechmann I, Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med. 2006;84:532-543.
72. Hemmer B, Cepok S, Nessler S, et al. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol. 2002;15:227-231.
73. Pohl-Koppe A, Burchett SK, Thiele EA, et al. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol. 1998;91:19-27.
74. Ichiyama T, Shoji H, Kato M, et al. Cerebrospinal fluid levels of cytokines and soluble tumour necrosis factor receptor in acute disseminated encephalomyelitis. Eur J Pediatr. 2002;161:133-137.
75. Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001;56:1308-1312.
76. Simon JH. Update on multiple sclerosis. Radiol Clin North Am. 2006;44:79-100. viii.
77. Chabas D, Green AJ, Waubant E. Pediatric multiple sclerosis. NeuroRx. 2006;3:264-275.
78. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
79. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988;38:180-185.
80. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology. 1988;38:1822-1825.
81. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
82. Hahn CD, Shroff MM, Blaser SI, et al. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology. 2004;62:806-808.
83. De Stefano N, Narayanan S, Matthews PM, et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain. 1999;122(Pt 10):1933-1939.
84. Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler. 2001;7:221-226.
85. Leary SM, Davie CA, Parker GJ, et al. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol. 1999;246:1023-1026.
86. Narayanan S, Francis SJ, Sled JG, et al. Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. Neuroimage. 2006;29:637-642.
87. De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol. 2002;59:1565-1571.
88. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125(Pt 10):2342-2352.
89. Matthews PM, De Stefano N, Narayanan S, et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol. 1998;18:327-336.
90. Wolinsky JS, Narayana PA. Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Curr Opin Neurol. 2002;15:247-251.
91. Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol. 1998;43:56-71.
92. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology. 1990;40:1764-1769.
93. De Stefano N, Matthews PM, Narayanan S, et al. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology. 1997;49:1138-1141.
94. Stefano ND, Narayanan S, Matthews PM, et al. Proton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter disorders. J Neurovirol. 2000;6(suppl 2):S121-S129.
95. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65-70.
96. De Stefano N, Narayanan S, Mortilla M, et al. Imaging axonal damage in multiple sclerosis by means of MR spectroscopy. Neurol Sci. 2000;21(suppl 2):S883-S887.
97. Tiberio M, Chard DT, Altmann DR, et al. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol. 2006;253:224-230.
98. Davie CA, Barker GJ, Thompson AJ, et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63:736-742.
99. Davies SE, Newcombe J, Williams SR, et al. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem. 1995;64:742-748.
100. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117(Pt 1):49-58.
101. Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging. 2005;15(suppl):46S-57S.
102. Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004;127(Pt 6):1361-1369.